Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib Effect on Rosuvastatin PK
NCT07088913Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capivasertib in cancer, sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity of rosuvastatin, Area under concentration-curve from time 0 to the last quantifiable concentration of rosuvastatin and 1 more. Started Jul 2025; status: completed.
02
Drugs
capivasertib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07088913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088913.